Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDI01 in Idiopathic Pulmonary Fibrosis
NCT06102083Phase 2Not yet recruiting
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of TDI01 in idiopathic pulmonary fibrosis (IPF), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
TDI01
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06102083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06102083.